Skip to main content

Table 2 Scintigraphic findings after 13-CRA therapy in 53 patients with radioiodine non-avid NMTC metastases

From: 13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study

WBS after redifferentiation therapy

Last pre redifferentiation WBS

 

No uptake

Uptake in thyroid bed

No scintigraphic response in metastases

35*

(66%)

8

(15%)

Scintigraphic response in metastases

8

(15%)

1

(2%)

   Lung

5

(9%)

0

(0%)

   Mediastinum

1

(2%)

1

(2%)

   Lung and lymph node

1

(2%)

0

(0%)

   Lung and bone

1

(2%)

0

(0%)

Persistent thyroid bed uptake in pre- and post-13-CRA RDT rxWBS

0

(0%)

1

(2%)

  1. 13-CRA, 13-cis-retinoic acid; RDT, re-differentiation therapy;
  2. rxWBS, post-therapy whole-body scintigraphy
  3. * in one patient there was only diagnostic WBC for comparison